We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

WATERS CORPORATION

Waters Corp. designs, manufactures, sells and services ultra performance liquid chromatography (UPLC), high performan... read more Featured Products: More products

Download Mobile App




UPLC-MS/MS Method Simultaneously Determines Plasma Catecholamines and Their Metabolites

By LabMedica International staff writers
Posted on 27 Jan 2021
Phaeochromocytomas and paragangliomas (PPGLs) are rare tumors of adrenal chromaffin cells or extra-adrenal paraganglia. More...
They are difficult to diagnose because of the non-specific clinical symptoms such as hypertension, palpitations, flushing and sweating.

Inappropriate catecholamines (CAs) production was normally used for the diagnosis of PPGLs in the clinical laboratory. New guideline recommends screening of fractionated urinary metanephrines (MNs, the metabolites of CAs) or plasma free MNs using high performance liquid chromatography with electrochemical detection (HPLC-ECD) or liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) as MNs are continuously secreted by the tumor.

Laboratory Medical Scientists at the Sichuan Provincial People’s Hospital (Sichuan, China) and their colleagues collected plasma samples in EDTA anticoagulant tubes by venipuncture in a seated position from patients. Plasma samples were pretreated with solid-phase extraction, followed by a 3-minute UPLC-MS/MS analysis to quantify epinephrine (E), norepinephrine (NE), dopamine (DA), metanephrine (MN), normetanephrine (NMN) and 3-methoxytyramine (3-MT), simultaneously.

A Waters ACQUITY I-Class UPLC coupled with Xevo TQ-S mass spectrometer (Waters Corporation, Milford, MA, USA) was used for analysis. Chromatographic separation was carried out using an Agilent Pursuit 3 PFP column (150 × 2.0 mm, 3.0 μm) (Agilent Technologies, Santa Clara, CA, USA) kept at 40 °C during analysis. The UPLC-MS/MS method was comprehensively verified and its diagnostic efficiency on PPGLs was tested using seven PPGLs and 408 non-PPGLs patient plasma samples.

After the UPLC-MS/MS method was verified, the seven PPGLs and 408 non-PPGLs patient plasma samples were used to assess its diagnostic efficiency. The median concentrations of the six analytes in the PPGLs patients were determined to be: E, 0.36 nmol/L; NE, 8.47 nmol/L; DA, 0.09 nmol/L; MN, 0.26 nmol/L; NMN, 6.26 nmol/L; and 3-MT, 5.35 pg/mL. The results showed that the median concentration of E of PPGLs group was significantly higher than that of cerebral hemorrhage group, but showed no significant difference to the other six non-PPGLs groups. The median concentration of NE of PPGLs group was significantly higher than almost all the non-PPGLs groups, except for cardiac diseases group. The median concentration of NMN of PPGLs group was significant higher than all non-PPGLs groups.

The authors concluded their study presented a UPLC-MS/MS method with high sensitivity and selectivity, good extraction recoveries and low matrix interferences for determining the concentrations of catecholamines and metabolites in human plasma. ROC curve analysis showed that the developed method provided excellent diagnostic performance in patients tested for PPGLs, which was validated to be an effective tool for screening or ruling out of PPGLs in clinical practice. The study was published on in the January 2021 issue of the journal Clinical Biochemistry.

Related Links:
Sichuan Provincial People’s Hospital
Waters Corporation
Agilent Technologies



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Candida Glabrata Test
ELIchrom Glabrata
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.